Sort   by:  
 Page size 
ProteomicsPrimary Myeloma Proteomics using Micro IST method
The myeloma cell surface proteome (“surfaceome�) not only determines tumor interaction with the microenvironment but serves as an emerging arena for therapeutic development. Here, we use glycoprotein capture proteomics to first define surface markers most-enriched on myeloma when compared to B-c...
ORGANISM(S): Homo sapiens (Human) 
2022-05-27 | PXD032031 | Pride
Myeloma 
ProteomicsMicro cell surface proteomics myeloma
The myeloma cell surface proteome (“surfaceome”) not only determines tumor interaction with the microenvironment but serves as an emerging arena for therapeutic development. Here, we use glycoprotein capture proteomics to first define surface markers most-enriched on myeloma when compared to B-cell ...
ORGANISM(S): Homo sapiens (Human) 
2022-05-27 | PXD022553 | Pride
Cell surface Plasma cell Multiple myeloma 
ProteomicsDefining the cell surface proteomic landscape of multiple myeloma reveals immunotherapeutic strategies and biomarkers of drug resistance
The myeloma cell surface proteome (“surfaceome”) not only determines tumor interaction with the microenvironment but serves as an emerging arena for therapeutic development. Here, we use glycoprotein capture proteomics to first define surface markers most-enriched on myeloma when compared to B-cell ...
ORGANISM(S): Homo sapiens (Human) 
2022-05-27 | PXD022482 | Pride
Cell surface Plasma cell Multiple myeloma Immunotherapy 
UnknownThe European Reference Network for Rare Neurological Diseases.
Not available
S-EPMC7840612 | biostudies-literature
UnknownGeneration and characterization of dickkopf3 mutant mice.
Not available
S-EPMC1430294 | biostudies-literature
ProteomicsDiscovery and Development of CD70 As a Cellular Therapy Target in High Risk Multiple Myeloma
Even in the BCMA CAR-T era, multiple myeloma (MM) patients with high-risk genotypes have the poorest outcomes. We thus leveraged MMRF CoMMpass data to identify potential novel surface immunotherapeutic targets in high-risk MM. As described below, we focused on CD70, an immunotherapeutic target known...
ORGANISM(S): Homo sapiens (Human) 
2025-11-27 | PXD048492 | Pride
Car-t Cd 70 Multiple myeloma Immunotherapy 
UnknownRisk factors and outcomes of pediatric non-invasive respiratory support failure in Latin America.
Not available
S-EPMC11997567 | biostudies-literature
UnknownThe COVID-19 pandemic and its global effects on dental practice. An International survey.
Not available
S-EPMC8285212 | biostudies-literature
UnknownBiomarker-guided intervention to prevent acute kidney injury after major surgery (BigpAK-2 trial): study protocol for an international, prospective, randomised controlled multicentre trial.
Not available
S-EPMC10069589 | biostudies-literature
UnknownINHALE-1: A Multicenter Randomized Trial of Inhaled Technosphere Insulin in Children With Type 1 Diabetes.
Not available
S-EPMC12818954 | biostudies-literature
Sort   by:  
 Page size